Direct Implantation of Patient Brain Tumor Cells into Matching Locations in Mouse Brains for Patient-Derived Orthotopic Xenograft Model Development

Simple Summary In this study, researchers tackled the challenge of advancing therapies for malignant brain tumors, given the scarcity of clinically relevant and biologically accurate mouse models. They introduced a novel surgical technique for transplanting fresh human brain tumor samples into SCID mice, accurately mimicking the original tumor’s location in the brain. Through this method, they successfully established 188 patient-derived orthotopic xenograft (PDOX) models from 408 brain tumor samples, preserving the histopathological and genetic traits of the original tumors. Success rates varied among tumor types, with high-grade glioma demonstrating the highest success rate. Overall, this technique presents a straightforward and effective approach for generating extensive cohorts of tumor-bearing mice for both biological investigations and preclinical drug evaluations, eliminating the necessity for a stereotactic frame. Abstract Background: Despite multimodality therapies, the prognosis of patients with malignant brain tumors remains extremely poor. One of the major obstacles that hinders development of effective therapies is the limited availability of clinically relevant and biologically accurate (CRBA) mouse models. Methods: We have developed a freehand surgical technique that allows for rapid and safe injection of fresh human brain tumor specimens directly into the matching locations (cerebrum, cerebellum, or brainstem) in the brains of SCID mice. Results: Using this technique, we successfully developed 188 PDOX models from 408 brain tumor patient samples (both high-and low-grade) with a success rate of 72.3% in high-grade glioma, 64.2% in medulloblastoma, 50% in ATRT, 33.8% in ependymoma, and 11.6% in low-grade gliomas. Detailed characterization confirmed their replication of the histopathological and genetic abnormalities of the original patient tumors. Conclusions: The protocol is easy to follow, without a sterotactic frame, in order to generate large cohorts of tumor-bearing mice to meet the needs of biological studies and preclinical drug testing.

[1]  Emily J. Girard,et al.  Preclinical Pediatric Brain Tumor Models for Immunotherapy: Hurdles and a Way Forward. , 2023, Neuro-oncology.

[2]  D. Brat,et al.  Targeting GBM with an Oncolytic Picornavirus SVV-001 alone and in combination with fractionated Radiation in a Novel Panel of Orthotopic PDX models , 2023, Journal of Translational Medicine.

[3]  T. Man,et al.  Epigenetic Alterations of Repeated Relapses in Patient-matched Childhood Ependymomas , 2022, Nature Communications.

[4]  Yongcheng Song,et al.  Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma , 2022, Translational oncology.

[5]  B. Teicher,et al.  Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies , 2021, Laboratory Investigation.

[6]  M. Kool,et al.  Spatial Dissection of Invasive Front from Tumor Mass Enables Discovery of Novel microRNA Drivers of Glioblastoma Invasion , 2021, Advanced science.

[7]  S. Pfister,et al.  International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer , 2021, Molecular Cancer Therapeutics.

[8]  C. Lau,et al.  Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors. , 2020, Cancer letters.

[9]  Mariella G. Filbin,et al.  Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma , 2020, Cancer cell.

[10]  C. Keller,et al.  Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Primary and Recurrent Meningioma , 2020, Cancers.

[11]  M. Kool,et al.  Molecular characterization of histopathological ependymoma variants , 2020, Acta Neuropathologica.

[12]  D. Haussler,et al.  Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design , 2019, Cell reports.

[13]  David T. W. Jones,et al.  The Molecular Landscape of ETMR at Diagnosis and Relapse , 2019, Nature.

[14]  Volker Hovestadt,et al.  Resolving medulloblastoma cellular architecture by single-cell genomics , 2019, Nature.

[15]  M. Kool,et al.  Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors , 2018, Journal of Neuro-Oncology.

[16]  Stephen T. C. Wong,et al.  Systems biology–based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma , 2018, Science Translational Medicine.

[17]  David T. W. Jones,et al.  A biobank of patient-derived pediatric brain tumor models , 2018, Nature Medicine.

[18]  Martin Sill,et al.  Heterogeneity within the PF-EPN-B ependymoma subgroup , 2018, Acta Neuropathologica.

[19]  Wende Li,et al.  Establishment and evaluation of four different types of patient-derived xenograft models , 2017, Cancer Cell International.

[20]  Yiling Lu,et al.  A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. , 2017, Cell reports.

[21]  Steven B. Neuhauser,et al.  PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. , 2017, Cancer research.

[22]  D. Parsons,et al.  Xenotransplantation of pediatric low grade gliomas confirms the enrichment of BRAF V600E mutation and preservation of CDKN2A deletion in a novel orthotopic xenograft mouse model of progressive pleomorphic xanthoastrocytoma , 2017, Oncotarget.

[23]  Roland Eils,et al.  The whole-genome landscape of medulloblastoma subtypes , 2017, Nature.

[24]  Steven J. M. Jones,et al.  Spatial heterogeneity in medulloblastoma , 2017, Nature Genetics.

[25]  M. Linnebacher,et al.  Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies , 2017, Journal of Translational Medicine.

[26]  M. Kool,et al.  Risk stratification of childhood medulloblastoma in the molecular era: the current consensus , 2016, Acta Neuropathologica.

[27]  David T. W. Jones,et al.  Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. , 2016, Cancer cell.

[28]  David T. W. Jones,et al.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.

[29]  Gary D. Bader,et al.  Divergent clonal selection dominates medulloblastoma at recurrence , 2016, Nature.

[30]  M. Kool,et al.  Molecular dissection of ependymomas , 2015, Oncoscience.

[31]  P. Rao,et al.  Cytogenetic landscape of paired neurospheres and traditional monolayer cultures in pediatric malignant brain tumors. , 2015, Neuro-oncology.

[32]  R. Hoffman.  Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts , 2015, Nature Reviews Cancer.

[33]  Gary D Bader,et al.  Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. , 2015, Cancer cell.

[34]  David T. W. Jones,et al.  Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers , 2015, Acta Neuropathologica.

[35]  C. Lau,et al.  A patient tumor-derived orthotopic xenograft mouse model replicating the group 3 supratentorial primitive neuroectodermal tumor in children. , 2014, Neuro-oncology.

[36]  G. Hannon,et al.  Patient-derived tumor xenografts: transforming clinical samples into mouse models. , 2013, Cancer research.

[37]  C. Lau,et al.  Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma. , 2013, Neuro-oncology.

[38]  R. Nardone,et al.  Match criteria for human cell line authentication: Where do we draw the line? , 2013, International journal of cancer.

[39]  Horatiu Voicu,et al.  Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. , 2012, Neuro-oncology.

[40]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.

[41]  M. Hollingshead,et al.  Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts , 2011, BMC biotechnology.

[42]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[43]  Scott L. Pomeroy,et al.  Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples , 2011, Acta Neuropathologica.

[44]  P. Rao,et al.  A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. , 2010, Neuro-oncology.

[45]  S. Horvath,et al.  Neurosphere Formation Is an Independent Predictor of Clinical Outcome in Malignant Glioma , 2009, Stem cells.

[46]  K. Wong,et al.  Direct Orthotopic Transplantation of Fresh Surgical Specimen Preserves CD133+ Tumor Cells in Clinically Relevant Mouse Models of Medulloblastoma and Glioma , 2008, Stem cells.

[47]  A. Björklund,et al.  In vitro characterization of a human neural progenitor cell coexpressing SSEA4 and CD133 , 2007, Journal of neuroscience research.

[48]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[49]  D. Bowers,et al.  Neuropsychological performance and quality of life of 10 year survivors of childhood medulloblastoma , 2005, Journal of Neuro-Oncology.

[50]  R. Mulhern,et al.  White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A. Gajjar,et al.  Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. , 2004, The oncologist.

[52]  Daniel H. Geschwind,et al.  Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[53]  R. Sen,et al.  Orthotopic Patient-Derived Glioblastoma Xenografts in Mice. , 2018, Methods in molecular biology.

[54]  Sohail Ahmed,et al.  The culture of neural stem cells , 2009, Journal of cellular biochemistry.

[55]  E. Maher,et al.  Mouse Models of Human Cancers Consortium Workshop on Nervous System Tumors. , 2006, Cancer research.

[56]  R. Hoffman.  Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. , 2005, Methods in molecular medicine.